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Abstract  6 
Objectives. The study was undertaken to examine the thermal and biochemical responses to 7 
a heat tolerance test (HTT) of malignant hyperthermia (MH) susceptible individuals, and 8 
compare these with the responses of volunteers who have suffered heat illness (HI) and 9 
control volunteers. 10 
Methods. Three groups of male volunteers (n=6 in each group) were recruited to the study:  11 
MHS  - civilian volunteers previously diagnosed as MH susceptible;  12 
EHI  - military volunteers with a history of exertional HI;  13 
CON - military volunteers with no history of HI or MH.  14 
For the HTT, volunteers walked on a treadmill at 60 % maximal oxygen uptake in an 15 
environmental chamber (mean [SD] temperature 35.5 [0.4] °C, relative humidity 43 [1] %). 16 
Measurements were made to assess thermoregulation and biochemistry. 17 
Results. There were no differences in deep body temperature, oxygen uptake or serum lactate 18 
concentrations between the three groups, although one MHS volunteer and two EHI 19 
volunteers failed to thermoregulate. Serum myoglobin concentration and the increase in 20 
serum myoglobin was higher in MHS than EHI and CON Post HHT (P<0.05). 21 
Conclusion. MH susceptibility does not always predispose an individual to heat intolerance 22 
during an acute HTT, but does appear to increase muscle breakdown. The inclusion of serum 23 
myoglobin measurements to a HTT may help to distinguish patients that are potentially MHS 24 
or have an underlying muscle myopathy, and who otherwise demonstrate thermal tolerance.   25 
 26 
 27 
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Introduction 28 
Exertional heat illness (EHI) describes the condition where an individual is incapacitated 29 
during or following exercise as a result of a rise in deep body temperature.1 In the United 30 
States, EHI is the third most common cause of sudden unexpected death in sport.2 Even in 31 
races in the United Kingdom, EHI is a significant occurrence: in the 2009 Great North Run, 55 32 
runners were admitted to the field hospital with deep body temperatures exceeding 41 °C.3 In 33 
the British Army, 361 cases of EHI were reported between 2007-2015 of which 137 were 34 
admitted to hospital,4 and in 2013 the deaths of three soldiers on a military training exercise 35 
in the Brecon Beacons were attributed to EHI.5  36 
 37 
It has been suggested that a skeletal muscle metabolic defect, similar to that responsible for 38 
malignant hyperthermia (MH) susceptibility could explain EHI in individuals with no obvious 39 
predisposing factors.6,7  MH presents under general anaesthesia with similar clinical features 40 
to EHI.  In affected individuals the anaesthetic triggering agents, such as isoflurane and 41 
sevoflurane, cause dysregulation of skeletal muscle calcium control leading to a progressive 42 
rise in cytoplasmic calcium concentration.8 The consequences are a rise in skeletal muscle 43 
cellular metabolism and contractile activity with increased oxygen consumption, carbon 44 
dioxide, hydrogen ion and heat production and rhabdomyolysis. The systemic effects include 45 
sympathetic stimulation, respiratory and metabolic acidosis, hyperthermia, hyperkalaemia and 46 
myoglobinaemia. The majority of cases of MH susceptibility are associated with variants in the 47 
ryanodine receptor 1 (RYR1) gene9 which encodes the skeletal muscle sarcoplasmic reticulum 48 
calcium release channel. Genetic screening has limited sensitivity and specificity, so definitive 49 
clinical diagnosis of MH susceptibility requires an open muscle biopsy with subsequent 50 
exposure of the freshly excised muscle to halothane and caffeine in an in-vitro contracture test 51 
(IVCT).10  52 
 53 
The Institute of Naval Medicine (INM), UK runs a Heat Illness Clinic (HIC), seeing 54 
approximately 140 British Armed Forces personnel a year. These individuals have suffered a 55 
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heat illness requiring admission to hospital with either central nervous system disturbance and 56 
/ or biochemical evidence of organ damage or rhabdomyolysis.  Patients referred to the clinic 57 
undertake a heat tolerance test (HTT) and those who demonstrate persistent heat intolerance 58 
(and in whom there is suspicion of metabolic skeletal muscle defect) are referred for testing 59 
for MH susceptibility. Of the 56 referred, 19 have met the laboratory criteria for MH 60 
susceptibility. Other studies, similarly report a high incidence of muscle abnormalities amongst 61 
individuals that have suffered EHI11 or rhabdomyolysis.12 Although several studies have 62 
compared the responses of MH susceptible individuals and volunteers to an exercise 63 
challenge, the findings are equivocal. On a progressive cycling test, aural but not rectal 64 
temperature was higher in MH susceptible volunteers, and it was suggested that the delayed 65 
rise in thumb temperature and the greater increase in free fatty acid and cortisol 66 
concentrations indicated abnormalities in heat dissipation and sympathetic activity in the MH 67 
susceptible volunteers.13 Whereas, studies using a 15 min cycling test and a two hour treadmill 68 
walk found no difference in oxygen uptake, sympathetic activity or muscle metabolism 69 
between MH susceptible volunteers and controls.14,15  70 
 71 
This study was undertaken to determine whether individuals already identified as MH 72 
susceptible would demonstrate abnormal thermoregulation on a HTT. It was hypothesised that 73 
MH susceptible volunteers would demonstrate a greater rate of rise in deep body temperature, 74 
serum lactate concentration and oxygen consumption, and greater changes in concentrations 75 
of biochemical markers suggestive of muscle breakdown, in response to a HHT than a control 76 
group and a group of volunteers with a history of EHI.  77 
 78 
Methods   79 
Three groups of male volunteers with 6 volunteers in each group were recruited to the study; 80 
each individual was tested once: 81 
MHS Group: active civilian volunteers with a personal or family history of MH and MH 82 
susceptibility confirmed by IVCT; 83 
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EHI Group: military patients of the INM HIC with previous history of EHI who were scheduled 84 
for evaluation by HTT;  85 
CON Group: military volunteers with no personal or family history suggestive of MH and with 86 
no history of HI.  87 
Written informed consent of the volunteers was gained in accordance with the Declaration of 88 
Helsinki.16 Absence of MH susceptibility in the EHI and CON groups was assumed rather than 89 
confirmed by IVCT because of the rarity of the condition and the invasive nature of the test. 90 
The volunteers were all European-white other than one volunteer in the EHI group who was 91 
non-Caucasian mixed race. 92 
 93 
Tests were conducted on a treadmill in an environmental chamber. Fans in front of the 94 
treadmill generated a wind speed of 7 km.hr-1. Preparation and recovery were conducted in 95 
an adjoining room (20-22 °C). Maximum oxygen uptake (V O2max) was measured using an 96 
incremental running test to volitional exhaustion with the volunteers wearing shorts and T.shirt. 97 
After rest for one hour the volunteers undertook the HTT which was conducted in three 98 
continuous phases walking on a treadmill with the volunteers wearing combat T.shirt, trousers, 99 
jacket, socks and trainers: 100 
Phase 1 (0-30 min): Volunteers carried a 14 kg rucksack, and walked on the treadmill with the 101 
speed and gradient set to elicit a work intensity equivalent to 60% V O2max.  102 
Phase 2 (30-45 min): At 30 min the rucksack and jacket were removed.  103 
Phase 3 (45-90 min): The T.shirt was removed at 45 min and the volunteers continued to walk 104 
on the treadmill until 60 min and were then stopped if a plateau (i.e. two consecutive readings 105 
the same) or fall in rectal temperature occurred; if rectal temperature was still rising the 106 
volunteer continued until a plateau occurred or 90 min had elapsed. If rectal temperature 107 
reached 39.5 °C the volunteer was stopped, removed from the chamber and actively cooled. 108 
An individual is considered to thermoregulate normally and demonstrate heat tolerance if they 109 
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attain a plateau in rectal temperature. Water was not allowed during the test, but drinking was 110 
actively encouraged in the recovery periods.  111 
 112 
ECG was monitored using a 6 lead ECG on-line telemetry system (VitalJacket, Optima-Life, 113 
London, UK).  114 
Rectal temperature (Tre) was monitored throughout the HTT using a disposable rectal 115 
thermistor (Variohm-Eurosensor Ltd, Towcester, UK) inserted 10 cm beyond the anal 116 
sphincter, and measurements recorded on a data logger (Grants, Cambridge, UK).  117 
Intestinal temperature (Tint) was measured using a telemetric pill (VitalSense, Mini Mitter 118 
Company Inc, Oregan, USA), swallowed two hours before beginning the HTT.  119 
Skin temperature and heat flow were measured using sensors (Concept Engineering, CT, 120 
USA) taped to the skin (at the right calf, right thigh, right arm, left upper chest, right scapula 121 
and mid-forehead). The output was recorded on a data logger (Grants, Cambridge, UK). The 122 
heat flow data (mV) were converted to watts and W.m-2 using the calibration constants 123 
supplied with the sensors and mean skin temperature (Msk) and mean heat flow calculated.  124 
Oxygen consumption and the respiratory measurements were made by analysing expired gas 125 
using an on-line system (Quark CPET, Cosmed, Rome, Italy).  126 
Whole body sweat loss was calculated from the change in nude body mass measured pre and 127 
post the HTT using calibrated scales (Sartorius, Epsom, UK), accuracy 0.001 kg.  128 
Localised sweat rates were measured using sweat capsules attached (using elasticated 129 
straps) at the base of the right scapular and thigh (Q-sweat, WR Medical Electronics Co., 130 
USA). Data were recorded continuously and 1 min averages calculated.  131 
Skin blood flow was measured by laser Doppler velocimetry (Moors Instruments MBF3D 132 
system, Axminster, UK) with probes attached with tape to the middle finger pad on the right 133 
hand, right forearm, mid right thigh, and right upper chest and recorded digitally to a computer 134 
(PowerLab, ADInstruments Ltd, UK). Data were recorded continuously, 1 min averages 135 
calculated and normalised to the percentage of the highest 5 min rolling average.  136 
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Blood samples were taken Pre, Post, 2 Hr Post and 20 Hr Post and analysed for serum lactate, 137 
creatine kinase (CK) and myoglobin concentrations. Lactate concentration was determined 138 
photometrically (AU680, Beckman Coulter, High Wycombe, UK) CV 2.59%. CK was analysed 139 
using the creatine phosphate to adenosine diphosphate method (AU 5800, Beckman Coulter, 140 
High Wycombe, UK) CV 3.2% and reference range (males) 25-195 U.L-1. Myoglobin 141 
concentration was determined using turbiometric analysis (COBAS 6000, Roche, Burges Hill, 142 
UK) CV <10% (reference range: 28-84 µg.L-1). 143 
Mean body temperature,17 rate of metabolic heat production, change in body heat storage, 144 
radiative, convective and evaporative heat transfer were calculated.18 145 
 146 
Descriptive data were produced and checked for normality. Normally distributed data were 147 
analysed using a one-way analysis of variance (ANOVA) or a general linear mixed model 148 
ANOVA. Post hoc comparisons were made by t-tests with Bonferroni correction. Data not 149 
normally distributed were analysed using the Kruskall-Wallis test and post-hoc comparisons 150 
using the Mann Whitney U with Bonferroni correction. 151 
 152 
Results 153 
Chamber temperature did not differ between the exposures for the three groups; mean (SD) 154 
dry, wet bulb and globe temperatures were 35.5 (0.4), 23.9 (0.2) and 35.2 (0.4) °C producing 155 
a mean (SD) WBGT of 27.3 (0.2) °C, relative humidity 43 (1)%. Age, height, body mass and 156 
lean body mass were the same for the three groups, mean (SD) values were 27 (5) years, 179 157 
(8) cm, 81.9 (12.9) kg and 68.2 (9.9) kg. Percentage body fat differed between the groups, 158 
F(2,15)=6.952 p=0.009; post hoc comparisons indicated that  the percentage body fat of the 159 
MHS group was lower than the EHI group (P=0.008), mean (SD) values were 12.3 (3.7) and 160 
19.9 (4.4) %. V O2max did not differ between the groups, mean values were 4.4 (0.8) L.min-1 161 
and 54.4 (7.4) mL.kg-1.min-1. Two of the MHS volunteers had experienced adverse reactions 162 
to anaesthesia and the remaining MHS volunteers underwent IVCT screening[15] as they had 163 
relatives who had experienced MH complications during anaesthesia. The halothane 164 
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threshold for three of the MHS volunteers was 0.5% and for the other three 2%, all six showed 165 
a variant in the RYR1 gene. Two of the MHS volunteers were professional sportsmen and the 166 
other four undertook recreational sports. 167 
 168 
During the HTT absolute V O2 and V O2 as a % V O2max did not differ between groups and 169 
there was no interaction between group and time. Rectal temperature for each volunteer is 170 
shown in Figure 1. Three volunteers (one from the MHS group and two from the EHI group) 171 
were withdrawn as their rectal temperatures reached 39.5°C and were rising. There was no 172 
effect of group nor an interaction between group and time on rectal temperature or intestinal 173 
temperature. Deep body and skin temperature, heart rate and localised sweat rate data for 174 
each phase of the test are shown in Table 1. Statistical analysis indicated that there were no 175 
interactions between phase and group for any of these variables. There was an effect of group 176 
on thigh temperature x2=10.491(2) (p=0.005), with MHS lower than CON (p=0.001) median 177 
values were 35.4°C and 36.4°C respectively. There was an effect of group on sweat rate at 178 
the thigh: x2=11.273 (2) (p=0.004) with post hoc comparisons indicating a higher rate in MHS 179 
than CON (p=0.001). Whole body sweat rate (WBSR), absolute and relative to body surface 180 
area did not differ between groups; median and (min-max) values for the volunteers were 1.32 181 
(0.75-2.08) L.hr-1 and 602 (429-1077) mL.m2.hr-1.  182 
 183 
There was no effect of group or an interaction between time and group for total mean heat 184 
flow, heat flow at the individual sites, skin blood flow and rate of metabolic heat production or 185 
radiative, convective and evaporative heat transfer. There was an effect of group F(2,15)=3.69 186 
(p=0.05) on cumulative heat storage (per kg body mass), with lower values for MHS than EHI 187 
(p=0.048). At 30 min mean (SD) cumulative heat storage for MHS was 50.8 (12.8) W.kg-1 and 188 
for EHI 71.1 (16.6) W.kg-1, at 50 min the corresponding values were 60.1 (20.7) W.kg-1 and 189 
88.4 (25.2) W.kg-1.  190 
 191 
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Serum myoglobin concentrations for MHS were higher than EHI and CON Post, x2=6.654 192 
(p=0.010); 2, Hr Post x2 =5.276 (p=0.022) and 20 Hr Post, x2 =3.872 (P=0.049). The increase 193 
in serum myoglobin was higher in MHS than EHI and CON from Pre to Post (x2=5.063 194 
[P=0.024]) and from Pre to 2 Hr Post (x2=5.936 [p=0.015]). There were no differences for 195 
serum CK or lactate concentrations, median values are given in Table 2. The serum myoglobin 196 
of the MHS volunteers with halothane thresholds of 0.5% were numerically higher than the 197 
volunteers with thresholds of 2%, median values Post and 2 Hr Post were 279 and 246 µg.L-1 198 
compared to 87 and 82 µg.L-1. 199 
 200 
Discussion 201 
Although one volunteer from the MHS group failed to thermoregulate during the HTT, there 202 
were no significant differences between the groups in terms of the deep body temperature, 203 
oxygen consumption and serum lactate measurements during the HTT. One interpretation of 204 
these findings is that, at the least, a large proportion of MH susceptible patients are not at 205 
increased risk of EHI and this is consistent with remarkably few reports of heat illness in MH 206 
susceptible patients.19,20 There was, however, evidence to suggest that the MHS group was 207 
able to dissipate heat more effectively, as demonstrated by their higher localised sweat rate 208 
and lower skin temperature at the thigh. Given that Tre and heat production were similar 209 
between the groups suggests that this was not sufficient to influence deep body temperature.  210 
 211 
Several studies have explored whether the response to exercise differs between volunteers 212 
with MHS and controls and in terms of deep body temperature the findings of this study are in 213 
agreement with those of Rutberg et al (1987)14 and Green et al (1987).21 Similar to this study, 214 
Green et al (1987) measured sweat evaporation using a ventilated capsule on the back and 215 
also found no significant difference between MHS and control volunteers,21 although the power 216 
to detect a difference in both studies was low because of the high variability of the 217 
measurement and low participant numbers. However, despite the small number of volunteers 218 
9 
 
the sweat rate measured at the thigh in our study was higher in MHS than CON. Interestingly, 219 
in an initial study examining the anthropometry of volunteers with MHS, Campbell et al (1982) 220 
showed that percentage body fat (as in this study) was lower in the MHS group (n=27) and 221 
was 16.7% compared with 21.3% in a control group (n=21).22 The current study used a more 222 
physically arduous regimen than the previous work and is the first reported to utilise a HTT 223 
with MHS volunteers; although Campbell et al (1983) and Green et al (1987) measured deep 224 
body temperature these only rose to mean values of 37.42 (±0.14) °C and approximately 38.2 225 
°C.13,21 226 
 227 
The findings are in contrast to the data from RYR1 knock-in mouse models of MH 228 
demonstrating consistent heat intolerance.23-25 To date four murine models have been 229 
developed each focusing on a specific variant, the most recent of these involves a variant 230 
carried by one of the volunteers in the MHS study group (p.Gly2434Arg),25 notably this was 231 
the volunteer who failed to thermoregulate.  232 
 233 
The data do support the hypothesis that the MHS group demonstrate a greater change in 234 
biochemical markers suggestive of muscle breakdown in response to a HHT than the CON 235 
and EHI groups. Serum myoglobin and muscle enzymes are indirect markers of muscle 236 
damage, and in a longitudinal study involving arduous military training, myoglobin was the 237 
most sensitive marker of muscle stress.26 During a MH reaction there is a sustained increase 238 
in myoplasmic calcium concentration producing hypermetabolism and contractile activity and 239 
it has been suggested that this also occurs with exercise in the heat.27 Calpain, a nonlysosomal 240 
cysteine protease is thought to trigger skeletal muscle protein breakdown and is activated by 241 
raised intracellular calcium.28  242 
 243 
Although there were only six volunteers in the MHS group, those who (on the IVCT) responded 244 
at 0.5% halothane demonstrated higher serum myoglobin values (at all three sample points 245 
after the HTT) than the MHS volunteers who responded to the IVCT at 2% halothane. This 246 
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suggests that sensitivity to halothane in the IVCT may correlate with the degree of muscle 247 
breakdown experienced in the HTT.  248 
 249 
Our study was limited because of the small number of MHS volunteers recruited, which was 250 
due to the low availability of suitable MHS volunteers. A further limitation of the study was the 251 
assumption that the control subjects were not susceptible to MH, but confirmation by IVCT 252 
could not be justified; however, none of these volunteers reported adverse reactions to 253 
anaesthesia in themselves or family members. While the HTT is able to discriminate between 254 
individuals based on their ability to thermoregulate under standard conditions, it is a surrogate 255 
for predisposition to develop EHI.  None of the volunteers in the MHS group have a history of 256 
EHI, so either they are not susceptible to EHI (including the one MHS individual who failed to 257 
thermoregulate during the HTT) or have not been exposed to the same level of exercise or 258 
heat as the military patients referred to the HIC and who subsequently fail the HTT. 259 
 260 
It is interesting that just one out of 6 MH susceptible individuals, who all had an abnormal 261 
IVCT, failed to thermoregulate during the HTT. This contrasts with the observation that 34% 262 
of patients referred to the HIC following an episode of EHI and unable to thermoregulate during 263 
the HTT have an abnormal IVCT.29 In reconciling these observations it is important to 264 
recognise that the IVCT is not specific for MH susceptibility and that abnormal findings may 265 
be obtained with samples from patients with other muscle disorders.30 Our working hypothesis 266 
is that MH susceptibility and susceptibility to EHI are distinct but overlapping phenotypes. 267 
Thus, there are some individuals susceptible to one but not the other, while other individuals 268 
are susceptible to both. This is a similar situation to the relationship between MH susceptibility 269 
and central core disease.8  270 
 271 
 272 
 273 
  274 
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Conclusions 275 
• Five out of 6 malignant hyperthermia susceptible individuals demonstrated 276 
thermotolerance on an acute heat tolerance test. 277 
• Malignant hyperthermia susceptibility appears to increase the magnitude of muscle 278 
breakdown on an acute HTT. 279 
• The inclusion of serum myoglobin measurements to a HTT may help to distinguish 280 
patients that are potentially MH susceptible.  281 
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Figure 1. Individual rectal temperatures. 400 
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Table 1. Temperature, heart rate and localised sweat rate (LSR) data at each Phase of 404 
the HTT, mean (SD) for variables with normally distributed data, and median 405 
(min-max) for variables not normally distributed (denoted by *), # significantly 406 
different to CON. 407 
 408 
 Phase 1 
(0-30 min) 
 
Phase 2 
 
Phase 3 
Clothing and equipment worn Trousers, jacket, 
T.shirt, rucksack 
Trousers, T.shirt Trousers 
Rectal (°C) All n=18 37.8 (0.3) 38.4 (0.3) 38.6 (0.4) 
Rectal rate of rise 
(°C.hr-1) 
All n=18 1.7 (0.4) 1.2 (0.7) 0.6 (0.7) 
Intestinal (°C) All n=16 37.8 (0.3) 38.5 (0.3) 38.6 (0.4) 
Heart rate 
(beats.min-1) 
All n=18 162 (17) 150 (18) 150 (19) 
Mean body (°C) All n=18 37.4 (0.3) 37.9  (0.4) 38.1 (0.4) 
Msk (°C) All n=18 35.9 (0.5) 35.6 (1.1) 35.8 (1.1) 
LSR Back 
(mL.m2.hr-1) 
All n=17 0.50 (0.26-0.93) 0.68 (0.31-1.12) 0.64 (0.29-1.03) 
 
LSR Thigh* 
(mL.m2.hr-1) 
#MHS(n=6) 0.21 (0.10-0.26) 0.24 (0.04-0.33) 0.25 (0.02-0.38) 
EHI (n=5) 0.19 (0.09-0.21) 0.17 (0.11-0.30) 0.12 (0.04-0.38) 
CON (n=6) 0.12 (0.07-0.19) 0.06 (0.03-0.22) 0.06 (0.03-0.17) 
 409 
 410 
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Table 2. Median (range) serum myoglobin, creatine kinase and lactate concentrations. 412 
 413 
  MHS (n=6) EHI (n=6) CON (n=6) 
 
Myoglobin 
(µg.L-1) 
Pre 60   (27-118) 50   (34-77) 55   (38-75) 
Post 142   (87-378) 79   (65-122) 69   (45-134) 
2 Hr Post 137   (81-280) 73   (52-135) 72   (50-139) 
20 Hr Post 79   (31-101) 52   (41-62) 49   (39-76) 
 
CK (U.L-1) 
Pre 276   (141-2963) 258   (126-890) 296  (199-412) 
Post 445   (194-2941) 315   (173-825) 314   (223-493) 
2 Hr Post 471  (198-2671) 321   (141-769) 296  (216-478) 
20 Hr Post 609   (176-1633) 336   (144-556) 238   (192-443) 
 
Lactate 
(mmol.L-1) 
Pre 1.6   (1.1-1.3) 1.3   (1.0-4.8) 1.6   (1.2-4.5) 
Post 1.4   (0.9-1.7) 1.7   (1.3-3.5) 1.4  (1.0-2.3) 
2 Hr Post 1.4   (1.1-3.2) 1.5   (1.2-2.1) 1.3   (1.1-1.9) 
20 Hr Post 1.5   (1.2-2.3) 1.7   (1.1-2.4) 1.1   (0.8-2.1) 
 414 
 415 
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Table 1b. Temperature, heart rate and localised sweat rate (LSR) data at each Phase of 417 
the HTT, mean (SD) for variables with normally distributed data, and median 418 
(min-max) for variables not normally distributed (denoted by *), # significantly 419 
different to CON. 420 
 421 
 Phase 1 
(0-30 min) 
 
Phase 2 
 
Phase 3 
Clothing and equipment worn Trousers, jacket, 
T.shirt, rucksack 
Trousers, T.shirt Trousers 
Rectal (°C) All n=18 37.8 (0.3) 38.4 (0.3) 38.6 (0.4) 
Rectal rate of rise 
(°C.hr-1) 
All n=18 1.7 (0.4) 1.2 (0.7) 0.6 (0.7) 
Intestinal (°C) All n=16 37.8 (0.3) 38.5 (0.3) 38.6 (0.4) 
Heart rate  MHS 163 (13) 146 (15) 148 (16) 
(beats.min-1) EHI 170 (15) 160 (16) 161 (20) 
 CON 154 (20) 144 (21) 141 (19) 
Mean body (°C) All n=18 37.4 (0.3) 37.9  (0.4) 38.1 (0.4) 
Msk (°C) All n=18 35.9 (0.5) 35.6 (1.1) 35.8 (1.1) 
LSR Back 
(mL.m2.hr-1) 
All n=17 0.50 (0.26-0.93) 0.68 (0.31-1.12) 0.64 (0.29-1.03) 
 
LSR Thigh* 
(mL.m2.hr-1) 
#MHS(n=6) 0.21 (0.10-0.26) 0.24 (0.04-0.33) 0.25 (0.02-0.38) 
EHI (n=5) 0.19 (0.09-0.21) 0.17 (0.11-0.30) 0.12 (0.04-0.38) 
CON (n=6) 0.12 (0.07-0.19) 0.06 (0.03-0.22) 0.06 (0.03-0.17) 
 422 
 423 
